FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366424910> ?p ?o ?g. }

• W4366424910 endingPage "2356" @default.
• W4366424910 startingPage "2356" @default.
• W4366424910 abstract "Metastatic prostate cancer (PCa) remains incurable and causes considerably diminished overall survival. Despite significant progress in pharmacotherapy, the disease prognosis remains unchanged. Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness in treating various advanced malignancies, but their efficacy in metastatic PCa is relatively limited. Previous studies have confirmed the immunosuppressive role of tumor-infiltrating B cells (TIL-Bs) in the PCa microenvironment, which accounts for their poor immunogenic potency. In this study, we demonstrated that an oral kinase agent, ibrutinib, strongly potentiated anti-PD-1 checkpoint blockade efficacy and successfully controlled tumor growth in a murine orthotopic PCa model constructed using a metastatic and hormone-independent cell line (RM-1). We identified close relationships between TIL-Bs, Bruton’s tyrosine kinase (BTK), and immunosuppressive molecules by bioinformatics and histological analysis. An in vitro study showed that a low dose of ibrutinib significantly inhibited B cell proliferation and activation as well as IL-10 production through the BTK pathway. Moreover, ibrutinib-treated B cells promoted CD8+ T cell proliferation and inhibitory receptor (IR) expression. However, the same dose of ibrutinib was insufficient to induce apoptosis in cancer cells. An in vivo study showed that ibrutinib monotherapy failed to achieve tumor regression in murine models but decreased B cell infiltration and inhibited activation and IL-10 production. More importantly, CD8+ T cell infiltration increased with high IR expression. Ibrutinib synergized with anti-PD-1 checkpoint blockade enormously improved antitumor immunity, thereby reducing tumor volume in the same scenario. These data set the scene for the clinical development of ibrutinib as an immunogenic trigger to potentiate anti-PD-1 checkpoint blockade for metastatic PCa immunotherapy." @default.
• W4366424910 created "2023-04-21" @default.
• W4366424910 creator A5003550548 @default.
• W4366424910 creator A5015448679 @default.
• W4366424910 creator A5032524322 @default.
• W4366424910 creator A5032872923 @default.
• W4366424910 creator A5034822328 @default.
• W4366424910 creator A5043394734 @default.
• W4366424910 creator A5049666235 @default.
• W4366424910 creator A5053398322 @default.
• W4366424910 creator A5065379006 @default.
• W4366424910 date "2023-04-18" @default.
• W4366424910 modified "2023-10-17" @default.
• W4366424910 title "Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer" @default.
• W4366424910 cites W1969438318 @default.
• W4366424910 cites W1980313076 @default.
• W4366424910 cites W2006236831 @default.
• W4366424910 cites W2054125735 @default.
• W4366424910 cites W2063227011 @default.
• W4366424910 cites W2089103836 @default.
• W4366424910 cites W2112927741 @default.
• W4366424910 cites W2140821709 @default.
• W4366424910 cites W2142604595 @default.
• W4366424910 cites W2157860451 @default.
• W4366424910 cites W2164035751 @default.
• W4366424910 cites W2168108459 @default.
• W4366424910 cites W2233614027 @default.
• W4366424910 cites W2514959772 @default.
• W4366424910 cites W2531934133 @default.
• W4366424910 cites W2582157939 @default.
• W4366424910 cites W2698159436 @default.
• W4366424910 cites W2765224588 @default.
• W4366424910 cites W2782689871 @default.
• W4366424910 cites W2945057866 @default.
• W4366424910 cites W2947014957 @default.
• W4366424910 cites W2950835870 @default.
• W4366424910 cites W2990771207 @default.
• W4366424910 cites W2999417355 @default.
• W4366424910 cites W3020771563 @default.
• W4366424910 cites W3025710496 @default.
• W4366424910 cites W3029235684 @default.
• W4366424910 cites W3103119004 @default.
• W4366424910 cites W3128646645 @default.
• W4366424910 cites W3129719839 @default.
• W4366424910 cites W3130892360 @default.
• W4366424910 cites W3153192485 @default.
• W4366424910 cites W3199680482 @default.
• W4366424910 cites W3208583765 @default.
• W4366424910 cites W4214947450 @default.
• W4366424910 cites W4223965717 @default.
• W4366424910 doi "https://doi.org/10.3390/cancers15082356" @default.
• W4366424910 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37190284" @default.
• W4366424910 hasPublicationYear "2023" @default.
• W4366424910 type Work @default.
• W4366424910 citedByCount "0" @default.
• W4366424910 crossrefType "journal-article" @default.
• W4366424910 hasAuthorship W4366424910A5003550548 @default.
• W4366424910 hasAuthorship W4366424910A5015448679 @default.
• W4366424910 hasAuthorship W4366424910A5032524322 @default.
• W4366424910 hasAuthorship W4366424910A5032872923 @default.
• W4366424910 hasAuthorship W4366424910A5034822328 @default.
• W4366424910 hasAuthorship W4366424910A5043394734 @default.
• W4366424910 hasAuthorship W4366424910A5049666235 @default.
• W4366424910 hasAuthorship W4366424910A5053398322 @default.
• W4366424910 hasAuthorship W4366424910A5065379006 @default.
• W4366424910 hasBestOaLocation W43664249101 @default.
• W4366424910 hasConcept C121608353 @default.
• W4366424910 hasConcept C126322002 @default.
• W4366424910 hasConcept C167672396 @default.
• W4366424910 hasConcept C170493617 @default.
• W4366424910 hasConcept C203014093 @default.
• W4366424910 hasConcept C2776090121 @default.
• W4366424910 hasConcept C2776107976 @default.
• W4366424910 hasConcept C2777701055 @default.
• W4366424910 hasConcept C2777938653 @default.
• W4366424910 hasConcept C2778461978 @default.
• W4366424910 hasConcept C2778468042 @default.
• W4366424910 hasConcept C2779878957 @default.
• W4366424910 hasConcept C2780192828 @default.
• W4366424910 hasConcept C2780851360 @default.
• W4366424910 hasConcept C3020616263 @default.
• W4366424910 hasConcept C42362537 @default.
• W4366424910 hasConcept C502942594 @default.
• W4366424910 hasConcept C71924100 @default.
• W4366424910 hasConcept C8891405 @default.
• W4366424910 hasConcept C90059517 @default.
• W4366424910 hasConcept C98274493 @default.
• W4366424910 hasConceptScore W4366424910C121608353 @default.
• W4366424910 hasConceptScore W4366424910C126322002 @default.
• W4366424910 hasConceptScore W4366424910C167672396 @default.
• W4366424910 hasConceptScore W4366424910C170493617 @default.
• W4366424910 hasConceptScore W4366424910C203014093 @default.
• W4366424910 hasConceptScore W4366424910C2776090121 @default.
• W4366424910 hasConceptScore W4366424910C2776107976 @default.
• W4366424910 hasConceptScore W4366424910C2777701055 @default.
• W4366424910 hasConceptScore W4366424910C2777938653 @default.
• W4366424910 hasConceptScore W4366424910C2778461978 @default.
• W4366424910 hasConceptScore W4366424910C2778468042 @default.

• next